Page 48 - Read Online

Guerriero et al. Hepatoma Res 2019;5:6 I http://dx.doi.org/10.20517/2394-5079.2018.108 Page 19 of 22

48. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular
carcinoma. J Hepatol 2012;56:167-75.
49. Zhou J, Yu L, Gao X, Hu J, Wang J, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J
Clin Oncol 2011;29:4781-8.
50. Zuo D, Chen L, Liu X, Wang X, Xi Q, et al. Combination of miR-125b and miR-27a enhances sensitivity and specificity of AFP-based
diagnosis of hepatocellular carcinoma. Tumour Biol 2016;37:6539-49.
51. Moshiri F, Salvi A, Gramantieri L, Sangiovanni A, Guerriero P, et al. Circulating miR-106b-3p, miR-101-3p and miR-1246 as
diagnostic biomarkers of hepatocellular carcinoma. Oncotarget 2018;9:15350-64.
52. Zhuang C, Jiang W, Huang D, Xu L, Yang Q, et al. Serum miR-21, miR-26a and miR-101 as potential biomarkers of hepatocellular
carcinoma. Clin Res Hepatol Gastroenterol 2016;40:386-96.
53. Xie Y, Yao Q, Butt AM, Guo J, Tian Z, et al. Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver
cirrhosis, and hepatocellular carcinoma. Cancer Biol Ther 2014;15:1248-55.
54. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, et al. Blood cell origin of circulating microRNAs: a cautionary note for
cancer biomarker studies. Cancer Prev Res (Phila) 2012;5:492-7.
55. Zheng XH, Cui C, Zhou XX, Zeng YX, Jia WH. Centrifugation: an important pre-analytic procedure that influences plasma microRNA
quantification during blood processing. Chin J Cancer 2013;32:667-72.
56. El-Garem H, Ammer A, Shehab H, Shaker O, Anwer M. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients
with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol 2014;6:818-24.
57. Fornari F, Ferracin M, Trerè D, Milazzo M, Marinelli S, et al. Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494,
identify cirrhotic patients with HCC. PLoS One 2015;10:e0141448.
58. Chen S, Chen H, Gao S, Qiu S, Zhou H, et al. Differential expression of plasma microRNA-125b in hepatitis B virus-related liver
diseases and diagnostic potential for hepatitis B virus-induced hepatocellular carcinoma. Hepatol Res 2017;47:312-20.
59. Guo X, Lv X, Lv X, Ma Y, Chen L, et al. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated
with distant metastasis. Oncotarget 2017;8:44050-8.
60. Zekri AN, Youssef AS, El-Desouky ED, Ahmed OS, Lotfy MM, et al. Serum microRNA panels as potential biomarkers for early
detection of hepatocellular carcinoma on top of HCV infection. Tumour Biol 2016;37:12273-86.
61. Tat Trung N, Duong DC, Tong HV, Hien TTT, Hoan PQ, et al. Optimisation of quantitative miRNA panels to consolidate the
diagnostic surveillance of HBV-related hepatocellular carcinoma. PLoS One 2018;13:e0196081.
62. Jarry J, Schadendorf D, Greenwood C, Spatz A, van Kempen LC. The validity of circulating microRNAs in oncology: five years of
challenges and contradictions. Mol Oncol 2014;8:819-29.
63. Cookson VJ, Bentley MA, Hogan BV, Horgan K, Hayward BE, et al. Circulating microRNA profiles reflect the presence of breast
tumours but not the profiles of microRNAs within the tumours. Cell Oncol (Dordr) 2012;35:301-8.
64. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis.
Nat Cell Biol 2014;16:717-27.
65. Su H, Yang JR, Xu T, Huang J, Xu L, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and
suppresses tumorigenicity. Cancer Res 2009;69:1135-42.
66. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. A microRNA expression signature of human solid tumors defines cancer
gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.
67. Meng FL, Wang W, Jia WD. Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma.
Med Oncol 2014;31:177.
68. Zhang JP, Zeng C, Xu L, Gong J, Fang JH, et al. MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of
hepatoma cells by targeting Met/Snail signaling. Oncogene 2014;33:4069-76.
69. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related
hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010;52:60-70.
70. Zhang JG, Shi Y, Hong DF, Song M, Huang D, et al. MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma
by targeting WNT1/beta-catenin pathway. Sci Rep 2015;5:8087.
71. Wang F, Ying H, He B, Pan Y, Sun H, et al. Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma.
Tumour Biol 2016;37:4945-53.
72. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance.
Biochem Biophys Res Commun 2011;406:70-3.
73. Yang L, Xu Q, Xie H, Gu G, Jiang J. Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance. Clin
Transl Oncol 2016;18:841-7.
74. Qu Z, Wu J, Wu J, Ji A, Qiang G, et al. Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma
diagnosis and prognosis. Oncotarget 2017;8:80666-78.
75. Shi M, Jiang Y, Yang L, Yan S, Wang YG, et al. Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular
carcinoma. J Cell Biochem 2018;119:4711-6.
76. Zheng J, Zhou Z, Xu Z, Li G, Dong P, et al. Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease
progression. Mol Med Rep 2015;12:1584-90.
77. Liu W, Hu J, Zhou K, Chen F, Wang Z, et al. Serum exosomal miR-125b is a novel prognostic marker for hepatocellular carcinoma.
Onco Targets Ther 2017;10:3843-51.
78. Wang H, Hou L, Li A, Duan Y, Gao H, et al. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma.
Biomed Res Int 2014;2014:864894.
79. Wang X, Zhang J, Zhou L, Lu P, Zheng ZG, et al. Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma